Literature DB >> 2244184

1,5-Anhydro-D-glucitol--a novel type of sugar in the human organism.

E Pitkänen1.   

Abstract

1,5-Anhydroglucitol is a six-carbon chain monosaccharide in C1-chair conformation with an oxygen ring in pyran position. The compound is a component of normal human blood serum. The concentration in serum fluctuates within a narrow range in a normal population. Very low serum concentrations are found in patients with diabetes mellitus. In insulin-dependent (type 1) diabetes with a long history of disease the concentration of 1,5-anhydroglucitol remains low in spite of improvement of glycaemic control by intensification of treatment, whereas in non-insulin dependent (type 2) diabetes the concentration gradually increases towards normal levels concomitantly with improvement in glycaemic control. The serum 1,5-anhydroglucitol concentration may be useful as an indicator of glycaemic control in patients with non-insulin dependent diabetes. Urinary excretion of 1,5-anhydroglucitol in normal subjects is very low inferring that the compound is efficiently reabsorbed by tubular cells. During glucosuria, induced by glucose tolerance test in human or streptozotocin administration in rats the 1,5-anhydroglucitol excretion is temporarily increased, which may be attributable to a competition between 1,5-anhydroglucitol and glucose for renal tubular transporters. Data so far obtained indicate that 1,5-anhydroglucitol may be either actively or passively transported through the cell membrane, depending on the cell type. Gas-liquid chromatography is the method of choice in the measurement of the low concentrations of 1,5-anhydroglucitol present in biological samples.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2244184

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  7 in total

1.  Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls.

Authors:  Sanjeev N Mehta; Natalie Schwartz; Jamie R Wood; Britta M Svoren; Lori Mb Laffel
Journal:  Pediatr Diabetes       Date:  2011-11-08       Impact factor: 4.866

2.  Renal tubular reabsorption of 1,5-anhydro-D-glucitol and D-mannose in vivo in the rat.

Authors:  E Pitkänen; O M Pitkänen
Journal:  Pflugers Arch       Date:  1992-03       Impact factor: 3.657

3.  Quantification of myo-inositol, 1,5-anhydro- D-sorbitol, and D-chiro-inositol using high-performance liquid chromatography with electrochemical detection in very small volume clinical samples.

Authors:  Karen J Schimpf; Claudia C Meek; Richard D Leff; Dale L Phelps; Daniel J Schmitz; Christopher T Cordle
Journal:  Biomed Chromatogr       Date:  2015-05-26       Impact factor: 1.902

4.  Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment.

Authors:  Eran Tallis; Cecile L Karsenty; Amanda B Grimes; Lina B Karam; Sarah H Elsea; Vernon Reed Sutton; Brandy L Rawls-Castillo; Ning Liu; Claudia Soler-Alfonso
Journal:  JIMD Rep       Date:  2022-05-22

5.  Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.

Authors:  Saskia B Wortmann; Johan L K Van Hove; Terry G J Derks; Nathalie Chevalier; Vijaya Knight; Andreas Koller; Esmee Oussoren; Johannes A Mayr; Francjan J van Spronsen; Florian B Lagler; Sommer Gaughan; Emile Van Schaftingen; Maria Veiga-da-Cunha
Journal:  Blood       Date:  2020-08-27       Impact factor: 22.113

6.  Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency.

Authors:  Maria Veiga-da-Cunha; Nathalie Chevalier; Xavier Stephenne; Jean-Philippe Defour; Nicole Paczia; Alina Ferster; Younes Achouri; Joseph P Dewulf; Carole L Linster; Guido T Bommer; Emile Van Schaftingen
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-09       Impact factor: 11.205

Review 7.  Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus.

Authors:  Margarita Ortiz-Martínez; Mirna González-González; Alexandro J Martagón; Victoria Hlavinka; Richard C Willson; Marco Rito-Palomares
Journal:  Curr Diab Rep       Date:  2022-03-10       Impact factor: 5.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.